Leqvio and Levothyroxine Interaction: What Patients and Clinicians Need to Know

Does Inclisiran Interact With Levothyroxine Directly?

No pharmacokinetic interaction between inclisiran and levothyroxine has been identified in clinical data or mechanistic analysis. Inclisiran works entirely through RNA interference inside hepatocytes and does not enter the CYP450 enzyme system that metabolizes most small-molecule drugs. Levothyroxine is absorbed passively across intestinal epithelium and is distributed and metabolized through thyroid hormone pathways unrelated to PCSK9 biology.

The FDA prescribing information for inclisiran (Leqvio) states that inclisiran is not a substrate, inducer, or inhibitor of CYP enzymes or major drug transporters including P-glycoprotein (P-gp), OATP1B1, OATP1B3, or BCRP. [1]

Why the Interaction Question Arises

Patients on levothyroxine are typically managing hypothyroidism long-term. Hypothyroidism is a secondary cause of hyperlipidemia, and clinicians often prescribe inclisiran specifically because statin therapy alone has not brought LDL-C to goal. The co-prescription is common.

The concern is understandable. Levothyroxine has a narrow therapeutic index and a well-documented list of absorption-level interactions with calcium, iron, proton-pump inhibitors, and bile acid sequestrants. [2] Clinicians reasonably ask whether a new lipid-lowering agent adds to that burden.

The Short Answer

It does not. Inclisiran is injected subcutaneously every six months; it bypasses the GI tract entirely after a 284 mg dose into the abdomen, thigh, or upper arm. There is no shared GI absorption window with levothyroxine. [1]

How Inclisiran Works: Mechanism Relevant to Drug Interactions

Inclisiran is a double-stranded small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc). After subcutaneous injection, GalNAc targets the asialoglycoprotein receptor (ASGPR) on hepatocytes, delivering the siRNA intracellularly. [3]

Inside the hepatocyte, inclisiran is incorporated into the RNA-induced silencing complex (RISC). RISC then cleaves PCSK9 mRNA, reducing PCSK9 protein synthesis. Less PCSK9 protein means more LDL receptors recycle to the hepatocyte surface, increasing LDL-C clearance from plasma.

No CYP450 or Transporter Involvement

Because inclisiran acts at the mRNA level inside a single cell type and is not itself a protein or small molecule processed by CYP450 or efflux transporters, it has an unusually clean drug-interaction profile. The ORION-1 phase 2 trial (N=501) conducted formal PK sub-studies and found no evidence of interaction with statins, ezetimibe, or other standard cardiovascular medications. [4]

Protein Binding and Elimination

Inclisiran binds to plasma proteins at roughly 87% after injection but is eliminated primarily through nuclease degradation in tissues, not hepatic CYP metabolism or renal filtration of intact drug. [1] This elimination route sidesteps the interaction mechanisms relevant to levothyroxine entirely.

How Levothyroxine Works and Where Its Interactions Occur

Levothyroxine (T4) is a synthetic form of the thyroid hormone thyroxine. After oral ingestion, roughly 40 to 80% of a dose is absorbed across the proximal small intestine and jejunum. [2] That absorption fraction is highly variable and is reduced by:

• Calcium carbonate, calcium citrate
• Ferrous sulfate and other iron salts
• Bile acid sequestrants (cholestyramine, colesevelam)
• Proton-pump inhibitors and H2 blockers
• Magnesium-containing antacids
• High-fiber or soy-based foods consumed simultaneously

The Narrow Therapeutic Index Problem

The FDA levothyroxine labeling explicitly lists these interactions and instructs patients to take levothyroxine on an empty stomach, 30 to 60 minutes before breakfast or other medications. [2] A TSH shift of even 1 to 2 mIU/L can change LDL-C by a clinically meaningful amount, discussed in the next section.

Why Inclisiran Is Not on That List

Inclisiran does not contact the GI tract in the levothyroxine absorption window. It is not a chelating agent, it does not alter gastric pH, it does not bind bile acids, and it is not a fiber or cation. Its subcutaneous delivery route means the two drugs simply do not share a mechanism capable of producing a direct interaction. [1] [3]

The Indirect Risk: Hypothyroidism as a Driver of Residual LDL-C

This is the clinically meaningful issue. Hypothyroidism reduces hepatic LDL receptor expression by a mechanism independent of PCSK9, increasing circulating LDL-C by 10 to 50 mg/dL depending on TSH severity. [5]

A patient prescribed inclisiran for atherosclerotic cardiovascular disease (ASCVD) who also has undertreated hypothyroidism may show a blunted LDL-C response to inclisiran, not because inclisiran is failing, but because the thyroid disorder is adding LDL-C through a separate pathway.

Evidence Linking Thyroid Status to LDL-C

A 2012 meta-analysis published in the Journal of Clinical Endocrinology and Metabolism (N=2,440 across 13 studies) found that each 1 mIU/L rise in TSH was associated with a 0.09 mmol/L (3.5 mg/dL) increase in total cholesterol in euthyroid individuals. [5] In overt hypothyroidism, total cholesterol rises can exceed 50 mg/dL above the patient's euthyroid baseline.

The American Association of Clinical Endocrinology (AACE) 2022 clinical practice guidelines state: "Dyslipidemia associated with hypothyroidism is expected to resolve with adequate thyroid hormone replacement and should be reassessed before initiating or intensifying lipid-lowering pharmacotherapy." [6]

What This Means for Inclisiran Prescribing

If a patient on levothyroxine has a TSH above the laboratory reference range (typically above 4.5 to 5.0 mIU/L) and is also receiving inclisiran, the clinician should:

1. Optimize levothyroxine dosing to achieve TSH within goal range (0.5 to 2.5 mIU/L for most adults with cardiovascular disease).
2. Recheck a fasting lipid panel 6 to 12 weeks after levothyroxine adjustment before concluding inclisiran is inadequate.
3. Avoid escalating lipid therapy solely on the basis of LDL-C measured during a period of suboptimal thyroid control.

This sequence prevents unnecessary therapy escalation and gives inclisiran a fair clinical trial under euthyroid conditions.

Inclisiran Efficacy Data: Knowing the Baseline Response to Expect

Understanding expected LDL-C reduction from inclisiran helps clinicians detect when an indirect thyroid-related effect is masking the drug's action.

ORION-10 and ORION-11

The ORION-10 trial (N=1,561, patients with ASCVD on maximally tolerated statins) showed inclisiran 284 mg reduced LDL-C by 51% from baseline at Day 510 versus placebo (P<0.001). [7] The ORION-11 trial (N=1,617, heterogeneous high-risk population) reported a 49.9% LDL-C reduction at Day 510 (P<0.001). [8]

A patient on stable statin and ezetimibe therapy who achieves only 15 to 20% LDL-C reduction after two inclisiran injections deserves a TSH check alongside reassessment of statin adherence.

ORION-9: Heterozygous Familial Hypercholesterolemia

ORION-9 (N=482, HeFH) showed a 39.7% mean LDL-C reduction at Day 510. [9] Patients with familial hypercholesterolemia have a higher baseline LDL-C burden, but thyroid status still modifies the achievable floor.

Durability and Dosing Schedule

Because inclisiran is dosed only twice yearly after the initial loading sequence, a single missed dose or a months-long period of undertreated hypothyroidism can affect an entire six-month measurement window. Optimizing thyroid status before each scheduled injection visit is a practical step that adds no cost or complexity.

Drug Interaction Profile of Inclisiran: Full Picture

Clinicians managing patients on multiple cardiovascular and endocrine medications need a clear picture of what inclisiran does and does not interact with.

Medications Inclisiran Does Not Interact With (Pharmacokinetically)

The ORION clinical program enrolled patients on statins (atorvastatin, rosuvastatin), ezetimibe, fibrates, aspirin, beta-blockers, ACE inhibitors, ARBs, and SGLT2 inhibitors. No dose adjustments for any of these co-medications were required. [1] [7] [8]

Levothyroxine sits in the same category: no pharmacokinetic adjustment is needed for either drug when they are co-prescribed.

Medications Requiring Caution Around Levothyroxine (Not Inclisiran)

The interaction burden in this co-prescription lives entirely on the levothyroxine side. The FDA levothyroxine label identifies over 20 drug classes with documented effects on levothyroxine absorption or metabolism. [2] These include:

• Bile acid sequestrants: colesevelam reduces T4 absorption and should be taken at least 4 hours apart from levothyroxine. [2]
• Calcium and iron supplements: separate by at least 4 hours.
• PPIs: omeprazole and pantoprazole reduce T4 absorption by raising gastric pH; monitor TSH 6 to 8 weeks after PPI initiation or dose change.
• Rifampin, phenytoin, carbamazepine: induce hepatic T4 metabolism, raising levothyroxine dose requirements.

None of these mechanisms apply to inclisiran.

Special Populations

The inclisiran FDA label notes no dose adjustment is needed in mild-to-moderate renal impairment or mild hepatic impairment. [1] Levothyroxine dose requirements increase in pregnancy; TSH targets shift to 0.1 to 2.5 mIU/L in the first trimester per the American Thyroid Association. [10] Neither condition alters the interaction conclusion.

Monitoring Parameters When Both Drugs Are Prescribed

Lipid Monitoring

Per the ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease, LDL-C should be checked 4 to 12 weeks after initiating a new lipid-lowering agent, then every 3 to 12 months to assess adherence and response. [11] For inclisiran specifically, the ORION trials used Day 90 and Day 180 measurements after each injection.

A practical schedule:

• Baseline fasting lipid panel before first inclisiran dose.
• Repeat at 3 months (Day 90).
• Repeat at 6 months before second dose (Day 180).
• Annually thereafter if stable.

Thyroid Monitoring

The American Thyroid Association recommends TSH measurement every 6 to 12 months in patients on stable levothyroxine replacement, with reassessment 6 to 8 weeks after any dose change. [10]

In a patient where LDL-C response to inclisiran appears lower than the 50% reduction seen in ORION trials, check TSH as part of the work-up before attributing failure to inclisiran.

When to Check TSH Outside the Routine Schedule

Add an off-cycle TSH check if:

• LDL-C reduction at Day 90 is below 30% on background maximally tolerated statin therapy.
• The patient reports new fatigue, weight gain, constipation, or cold intolerance suggesting decompensated hypothyroidism.
• A new medication with known levothyroxine absorption interference was started (e.g., calcium supplementation, a new PPI, or colesevelam for lipid lowering).

Patient Counseling Points

For Patients Starting Inclisiran While on Levothyroxine

1. Inclisiran is a twice-yearly injection. It does not interfere with your thyroid medication.
2. Take levothyroxine exactly as prescribed, on an empty stomach, 30 to 60 minutes before breakfast and other medications. This timing rule does not change because of inclisiran.
3. If your doctor starts a new calcium, iron, or antacid product, tell your pharmacist. These can reduce how much levothyroxine your body absorbs, which can indirectly affect your cholesterol levels.
4. Get your TSH and cholesterol checked on the schedule your doctor recommends. A rising TSH can raise LDL-C and make it look like inclisiran is not working.

For Patients Asking "Can I Take Leqvio With Levothyroxine?"

Yes. No dose adjustment is required for either drug. The injection timing relative to levothyroxine is irrelevant because inclisiran goes under the skin, not into the stomach. What matters is keeping thyroid levels controlled so the full cholesterol-lowering effect of inclisiran can be measured accurately.

Injection Site and Administration Reminders

Inclisiran 284 mg is injected subcutaneously into the abdomen, upper arm, or thigh by a healthcare provider in a clinical setting. Patients do not self-inject. [1] The dosing schedule (Day 1, Month 3, then every 6 months) means most patients receive only two to three injections per year, reducing the day-to-day drug management burden compared with daily oral lipid-lowering agents.

Summary Table: Inclisiran vs. Levothyroxine Interaction Assessment

| Parameter | Finding | |---|---| | Direct pharmacokinetic interaction | None identified | | CYP enzyme involvement | Inclisiran: none. Levothyroxine: CYP-inducers affect T4 metabolism, not inclisiran | | GI absorption overlap | None; inclisiran is subcutaneous | | P-glycoprotein involvement | Inclisiran: not a substrate or inhibitor | | Indirect interaction risk | High if TSH is uncontrolled; raises LDL-C independently | | Dose adjustment required | No adjustment for either drug | | Monitoring priority | TSH every 6 to 12 months; lipid panel at 3 and 6 months post-inclisiran | | Patient counseling priority | Maintain levothyroxine timing discipline; report new supplements or GI drugs |